三爱健康集团二零二三年中期报告

BOARDOFDIRECTORS ExecutiveDirectorsMr.ChenChengqingProfessorZhangRongqingMr.GaoBorui Mr.YuanChaoyangMr.SheHao Non-executiveDirector Mr.XiuYuan IndependentNon-executiveDirectors ProfessorZhuYiZhunMr.KhorKhieLiemAlexMr.ZhangRuigen COMPANYSECRETARY Ms.LiYuenShan AUTHORIZEDREPRESENTATIVES Mr.SheHao Ms.LiYuenShan AUDITCOMMITTEE Mr.KhorKhieLiemAlex(Chairman) ProfessorZhuYiZhunMr.ZhangRuigen REMUNERATIONCOMMITTEE Mr.KhorKhieLiemAlex(Chairman) ProfessorZhuYiZhunMr.ZhangRuigen ProfessorZhangRongqing 董事会执行董事陈成庆先生张荣庆教授高伯瑞先生袁朝阳先生畲昊先生 非执行董事 修远先生 独立非执行董事 朱依谆教授许麒麟先生张瑞根先生 公司秘书 李婉珊女士 法定代表畲昊先生李婉珊女士 审核委员会 许麒麟先生（主席）朱依谆教授 张瑞根先生 薪酬委员会 许麒麟先生（主席）朱依谆教授 张瑞根先生张荣庆教授 CorporateInformation 公司资料 NOMINATIONCOMMITTEE Mr.ZhangRuigen(Chairman) ProfessorZhuYiZhunMr.KhorKhieLiemAlex ProfessorZhangRongqing AUDITOR MazarsCPALimited HONGKONGLEGALADVISOR RaymondSiu&LawyersUnits1302–1303&1802 RuttonjeeHouseRuttonjeeCentre11DuddellStreetCentral,HongKong PRINCIPALBANKERS NanyangCommercialBankLimitedHangSengBankLimited ChinaConstructionBank IndustrialandCommercialBankofChinaLimitedChinaCITICBankCorporationLimited REGISTEREDOFFICE GrandPavilionHibiscusWay 802WestBayRoad P.O.Box31119KY1-1205CaymanIslands 提名委员会 张瑞根先生（主席）朱依谆教授 许麒麟先生张荣庆教授 核数师 中审众环（香港）会计师事务所有限公司 香港法律顾问萧镇邦律师行香港中环 都爹利街11号律敦治中心律敦治大厦 1302–1303及1802室 主要往来银行 南洋商业银行有限公司恒生银行有限公司 中国建设银行 中国工商银行股份有限公司中信银行股份有限公司 注册办事处GrandPavilionHibiscusWay 802WestBayRoad P.O.Box31119KY1-1205CaymanIslands PRINCIPALPLACEOFBUSINESSINHONGKONG Unit5,7/F.NanyangPlaza57HungToRoadKwunTong Kowloon,HongKong SHAREREGISTRARSANDTRANSFEROFFICES Principalshareregistrarandtransferoffice RoyalBankofCanadaTrustCompany(Cayman)Limited 4thFloor,RoyalBankHouse 24SheddenRoad,GeorgeTownGrandCaymanKY1-1110CaymanIslands HongKongbranchshareregistrarandtransferoffice ComputershareHongKongInvestorServicesLimited 17MFloorHopewellCentre 183Queen’sRoadEastWanchai,HongKong STOCKCODE 1889 WEBSITE www.1889hk.com 香港主要营业地点 香港九龙观塘 鸿图道57号南洋广场7楼5室 股份过户登记处 股份过户登记总处 RoyalBankofCanadaTrustCompany (Cayman)Limited 4thFloor,RoyalBankHouse 24SheddenRoad,GeorgeTownGrandCaymanKY1-1110CaymanIslands 股份过户登记处香港分处香港中央证券登记有限公司香港湾仔 皇后大道东183号 合和中心 17M楼 股份代号 1889 网址 www.1889hk.com Theboard(the“Board”)ofdirectors(the“Directors”)ofSanaiHealthIndustryGroupCompanyLimited(“SanaiHealthIndustry”orthe“Company”)herebypresentstheunauditedcondensedconsolidatedfinancialstatementsoftheCompanyanditssubsidiaries(collectivelyreferredtothe“Group”)forthesix-monthperiodended30June2023(the“CurrentPeriod”),togetherwiththecomparativefiguresforthecorrespondingperiodin2022. BUSINESSREVIEW DuringtheCurrentPeriod,theGroupwasprincipallyengagedinthreebusinesses:(i)pharmaceuticalproductsbusiness;(ii)financeleasingbusiness;and(iii)genetictestingandmoleculardiagnosticservices.Thethreebusinessarestatedasbelow: PharmaceuticalProductsBusiness SincethesuccessfultransferoftheproductionlineoftheGroupfromour51%-ownedsubsidiarytoourwholly-ownedsubsidiaryinAugust2022,thecoreproductioncentreaswellastheexclusivesaleschanneloftheGroup’sowndevelopedpharmaceuticalproductshasbeenkeptundercontrolofourwholly-ownedsubsidiaryduringtheCurrentPeriod.Assuch,theGrouphasbeenabletoincreaseitsshareofprofitgeneratedfromthesalesofthissegmentasasignificantportionofsuchprofitisnolongerrequiredtobesharedbythenon-controllinginterestsofour51%-ownedsubsidiaryasinthepastyears.Giventheaforesaid,despitethefactthattherehasbeenaverysubstantialincreaseinthegeneralcostoftraditionalChineseherbalmaterialsinthePRCsincethestartoftheyearof2023whichhasinevitablyaffectedthegrossprofitmarginofthesalesofourowndevelopedpharmaceuticalproductsintheCurrentPeriod,theGroupwasstillabletoincreasetheprofitattributabletoourshareholdersintheCurrentPeriod. 三爱健康产业集团有限公司（“三爱健康产业”或“本公司”）董事（“董事”）会（“董事会”）谨此提呈本公司及其附属公司（统称 “本集团”）截至二零二三年六月三十日止六个月期间（“本期间”）的未经审核简明综合 财务报表，连同二零二二年同期的比较数字。 业务回顾 于本期间内，本集团主要从事三项业务：(i)医药产品业务；(ii)融资租赁业务；及(iii)基因检测及分子生物诊断服务。该三项业务载述如下： 医药产品业务 自二零二二年八月本集团成功将生产线从我们拥有51%股权的附属公司转移到我们全资拥有的附属公司起，核心生产中心以及本集团自主研发医药产品的独家销售渠道于本期间一直在我们全资拥有的附属公司控制下。因此，由于我们拥有51%股权的附属公司的非控股权益不再按往年分占该分部销售所得的大部分溢利，故本集团能够增加分占有关溢利的份额。鉴于上文所述，尽管自二零二三年开始，中国传统中药材的一般成本大幅增加，不可避免地影响了本期间自主研发医药产品的销售毛利率，但本集团仍能增加本期间股东应占溢利。 TheGroupwilltakeamorecautiousapproachtoincreaseitsmarketsharebyexpandingitsproductioncapacityandpromotingitsowndevelopedpharmaceuticalproductsastheactualpaceandprogressofeconomicrecoveryinChinahasnotbeenaspromisingandencouragingasoriginallyexpectedandforecastedduringtheCurrentPeriod. FujianZhixin,anindirectwholly-ownedsubsidiaryoftheCompany,actsasasalesagentnationwidefortheherbalmedicalmaterials,Chineseherbalmedicine,Chinesepatentmedicine,chemicaldrugpreparations,antibioticpreparations,biochemicalpharmaceuticals,biologicalproducts,healthcareproductsandfoodproducts. DuringtheCurrentPeriod,therevenuederivedfromthepharmaceuticalproductsbusinessincreasedby5.1%toapproximatelyRMB49.15million(2022interim:approximatelyRMB46.76million).TheprofitderivedfromthepharmaceuticalproductsbusinesshasdecreasedtoRMB12.2millionfortheCurrentPeriod,representingadecreaseofapproximately52.4%as